Antibodies with modulated glycan profiles

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 12084686
APP PUB NO 20210062156A1
SERIAL NO

17051528

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to recombinantly-expressed denosumab molecules and methods for modulating glycan profiles of denosumab molecules.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AMGEN INCONE AMGEN CENTER DRIVE M/S 28-2-C THOUSAND OAKS CA 91320

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brandenstein, Michael Charles Woodinville, US 8 7
Crowell, Christopher Kenyon Thousand Oaks, US 9 0
Gillespie, Alison Jean Seattle, US 2 0
Kitchen, Neil Alberta, CA 2 0
Petrovan, Simina Crina Lynnwood, US 8 7
Wu, Jian Acton, US 427 2508

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 10, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 10, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 10, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00